Podcasts

Recent Episodes

September 4, 2026

Current Approaches and Future Directions for Early-Stage TNBC

September 1, 2026

A Breast Radiologist Breaks Down Breast Cancer Screening Guidelines: With Sara Nunnery, MD, MSCI; and Dana Bonaminio, MD

August 31, 2026

Non–Small Cell Lung Cancer 2026 UPDATE

Michael K. Wong, MD, Roswell Park Comprehensive Cancer Center

August 28, 2026

FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC

Eric D. Whitman, MD, and Francis Paul Worden, MD, discuss the integration of immunotherapy into the CSCC treatment paradigm.

August 28, 2026

Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD

$Sagar Lonial, MD, FACP, FASCO, shares the significance of the FDA approval of iberdomide/daratumumab/dexamethasone in replased/refractory multiple myeloma.$

August 27, 2026

FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

August 24, 2026

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

August 21, 2026

Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD

August 20, 2026

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

Sara Nunnery, MD, MSCI; Eleonora Teplinsky, MD

August 18, 2026

Breast Cancer Endocrine Therapy Profiles Prompt Individualized Toxicity Management Conversations: With Sara Nunnery, MD, MSCI; and Eleonora Teplinsky, MD

All series

All Podcasts

Current Approaches and Future Directions for Early-Stage TNBC

September 4th 2026

OncLive On Air®

A Breast Radiologist Breaks Down Breast Cancer Screening Guidelines: With Sara Nunnery, MD, MSCI; and Dana Bonaminio, MD

BySara Nunnery, MD, MSCI,Dana Bonaminio, MD

September 1st 2026

Drs Nunnery and Bonaminio discuss breast cancer screening amid recent conflicting guidelines, beginning with an overview of the breast radiologist's role.

Non–Small Cell Lung Cancer 2026 UPDATE

BySamantha A. Armstrong, MD,Karine Tawagi, MD

August 31st 2026

Two Onc Docs gives a board-focused review of early-stage and locally advanced NSCLC, reflecting recent shifts in staging and perioperative therapy.

FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC

ByMichael Wong, MD, PhD, FRPC

August 28th 2026

Dr Wong discusses the significance of the FDA’s accelerated approval of vusolimogene oderparepvec-wtpg plus nivolumab in unresectable advanced cutaneous melanoma.

Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD

ByEric Whitman, MD,Francis Worden, MD

August 28th 2026

Eric D. Whitman, MD, and Francis Paul Worden, MD, discuss the integration of immunotherapy into the CSCC treatment paradigm.

$Sagar Lonial, MD, FACP, FASCO, shares the significance of the FDA approval of iberdomide/daratumumab/dexamethasone in replased/refractory multiple myeloma.$

FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

BySagar Lonial, MD,Chris Ryan

August 27th 2026

Sagar Lonial, MD, FACP, FASCO, shares the significance of the FDA approval of iberdomide/daratumumab/dexamethasone in replased/refractory multiple myeloma.

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

August 24th 2026

OncLive On Air®

Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD

ByChandler Park, MD, MSc, FACP,Joshua Brody, MD, of Mount Sinai Hospital

August 21st 2026

Drs Park and Brody discuss the evolving frontline and relapsed treatment landscape in Hodgkin lymphoma.

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

ByJennifer B. Valerin, MD, PhD

August 20th 2026

Dr Valerin discusses the role of liposomal irinotecan in pancreatic cancer management and factors influencing the decision to use this agent in practice.

Breast Cancer Endocrine Therapy Profiles Prompt Individualized Toxicity Management Conversations: With Sara Nunnery, MD, MSCI; and Eleonora Teplinsky, MD

BySara Nunnery, MD, MSCI,Eleonora Teplinsky, MD

August 18th 2026

Drs Nunnery and Teplinsky discussed how to manage the adverse effects associated with endocrine therapy in hormone receptor–positive breast cancer.

Key Considerations for Health Equity and Patient-Centered Care in TNBC

August 17th 2026

OncLive On Air®

FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD

ByAdam M. Brufsky, MD, PhD

August 14th 2026

Dr Brufsky discusses the FDA approval of gedatolisib plus fulvestrant ± palbociclib for hormone receptor–positive, PIK3CA wild-type advanced breast cancer.

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

ByJonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

August 7th 2026

Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

BySara Nunnery, MD, MSCI,Sarah Sunshine, MD

August 4th 2026

Drs Nunnery and Sunshine discuss how breast cancer therapies affect the eye, beginning with a primer on ocular anatomy.

From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

August 3rd 2026

OncLive On Air®

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

ByDouglas W. Sborov, MD, MS

July 31st 2026

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

Solange Peters, MD, PhD, University Hospital of Lausanne

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

BySolange Peters, MD, PhD

July 31st 2026

Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in NSCLC, rather than sequencing them.

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

ByChandler Park, MD, MSc, FACP,Stephen Liu, MD

July 31st 2026

Drs Park and Liu discuss precision oncology, bispecific antibodies, and next-generation targeted therapies in NSCLC.

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

ByTanios Bekaii-Saab, MD, FACP

July 30th 2026

Dr Bekaii-Saab discusses the current state of the metastatic colorectal cancer treatment landscape and potential future research directions.

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

ByJohn N. Allan, MD

July 30th 2026

John N. Allan, MD, discusses all things regarding fixed-duration regimens in CLL from a review of the most pivotal data for the topic.

Marlana M. Orloff, MD, the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

ByMarlana M. Orloff, MD

July 29th 2026

Dr Orloff discusses the distinct biology of uveal melanoma and why it has historically resisted systemic treatment.

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

ByMisty D. Shields, MD, PhD,Triparna Sen, PhD,Ditte Primdahl, MD

July 28th 2026

Lung cancer and neurology experts discuss the ties between cancer-associated LEMS and small cell lung cancer, diagnostic tips, and management strategies.

FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD

ByEverett Meyer, MD, PhD

July 28th 2026

Everett Meyer, MD, PhD, discusses the significance of the FDA approval of Orca-T for patients with hematologic malignancies.

ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

ByPaolo Tarantino, MD

July 27th 2026

Dr Tarantino discusses practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting.

FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

BySara M. Tolaney, MD, MPH

July 27th 2026

Dr Tolaney discusses the FDA approval of first-line sacituzumab govitecan plus pembrolizumab for locally advanced or metastatic PD-L1–positive TNBC.

FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

ByJorge Cortes, MD,Elias Jabbour, MD

July 27th 2026

Dr Cortes and Dr Jabbour discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 FDA approval for patients with CML.

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

July 24th 2026

OncLive On Air® CE

Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at NYU Langone Health’s Perlmutter Cancer Center

Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD

ByJoshua K. Sabari, MD

July 24th 2026

Joshua K. Sabari, MD, discusses the complexities of managing SCLC across both academic and community settings.

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

July 23rd 2026

OncLive On Air® CE

Sara Nunnery, MD, MSCI, breast medical oncologist, director, Breast Cancer Research, Tennessee Oncology in Nashville; Maelee Yang, MD, plastic surgeon, The Surgical Clinic; Odette Abou Ghanem, MD, assistant professor, plastic and reconstructive surgery, plastic and reconstructive surgeon, Vanderbilt University Medical Center

Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD

BySara Nunnery, MD, MSCI,Maelee Yang, MD ,Odette Abou Ghanem, MD

July 21st 2026

Drs Nunnery, Yang, and Abou Ghanem discuss available breast reconstruction options following breast cancer surgery.

Podcasts

Recent Episodes

All series

Oncology Unplugged With Dr Chandler Park

Pediatrics

Breast Cancer Briefing

Marvels in Medicine

One for Minutes With Markman

Talking Tumors

Ask Me Anything

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

OncLive on Air Powered by PER

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

Current Approaches and Future Directions for Early-Stage TNBC

A Breast Radiologist Breaks Down Breast Cancer Screening Guidelines: With Sara Nunnery, MD, MSCI; and Dana Bonaminio, MD

Non–Small Cell Lung Cancer 2026 UPDATE

FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC

Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD

FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD

Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

Breast Cancer Endocrine Therapy Profiles Prompt Individualized Toxicity Management Conversations: With Sara Nunnery, MD, MSCI; and Eleonora Teplinsky, MD

Key Considerations for Health Equity and Patient-Centered Care in TNBC

FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD

ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Post-Breast Cancer Reconstruction Options Center Patient Preferences and Oncologic Expertise: With Sara Nunnery, MD, MSCI; Maelee Yang, MD; and Odette Abou Ghanem, MD

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

CARiBOU Regimen Drives Complete Metabolic Responses in First-Line Mantle Cell Lymphoma

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC